Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Neurological Disorders Clear all
Terminated Not applicable Interventional Results available

Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects

NCT01736267
View directory record Official record
Conditions
Bilateral Hearing Loss for Causes Other Than Tumors
Interventions
Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 27, 2026, 5:09 AM EDT
Completed No phase listed Observational

Study on Moebius Syndrome and Congenital Facial Weakness Disorders

NCT02055248
View directory record Official record
Conditions
Brain Disorders, Birth Defects, Craniofacial Differences
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

EMD 128130 for the Treatment of Parkinson's Disease

NCT00009048
View directory record Official record
Conditions
Parkinson's Disease
Interventions
EMD 128130, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 5:09 AM EDT
Enrolling by invitation No phase listed Observational

Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic

NCT06095284
View directory record Official record
Conditions
Dementia
Interventions
Pre-Extraction Phase, Extraction Phase, Post-Extraction Phase
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
22,500,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 27, 2026, 5:09 AM EDT
Completed No phase listed Observational

Pediatric Patients With Metabolic or Other Genetic Disorders

NCT02769949
View directory record Official record
Conditions
Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome, Developmental Delay
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

NCT04010305
View directory record Official record
Conditions
Agitation, Schizophrenia
Interventions
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

NCT04238819
View directory record Official record
Conditions
Relapsed Solid Tumor, Refractory Solid Tumor
Interventions
Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

NCT03955939
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
LY3295668 Erbumine, Endocrine therapy, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 27, 2026, 5:09 AM EDT
Completed No phase listed Observational

Pediatric Bipolar Registry

NCT02360267
View directory record Official record
Conditions
Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 27, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional

Steroid Injections Given at the "Level of MRI Pathology" Versus at the "Level of Clinical Symptoms" to See if One is More Effective Than the Other.

NCT02196883
View directory record Official record
Conditions
Radiculopathy, Spinal Stenosis, Intervertebral Disc Displacement
Interventions
Transforaminal Epidural Steroid Injection
Procedure
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Timeline
Started 2014
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

NCT02535923
View directory record Official record
Conditions
Insomnia, Psychosis
Interventions
Cognitive Behavioral Therapy-Insomnia, Health and Wellness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 27, 2026, 5:09 AM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

NCT00795730
View directory record Official record
Conditions
Alzheimer Disease, Healthy Subjects
Interventions
NSA-789, placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

NCT01111097
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

NCT07038876
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, ML-007C-MA BID, ML-007C-MA QD
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Not listed No phase listed Observational

Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M

NCT04066933
View directory record Official record
Conditions
Complex Regional Pain Syndromes, Neuralgia, Thoracic Outlet Neurologic Syndrome
Interventions
A2M enriched plasma
Combination Product
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
23 Years to 77 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 27, 2026, 5:09 AM EDT
Not yet recruiting Not applicable Interventional

LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)

NCT07710989
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucinations
Interventions
LIFU
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

NCT01459302
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

NCT00662870
View directory record Official record
Conditions
Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 84 Days
Enrollment
1,941 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
26
States / cities
Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 27, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation

NCT05445466
View directory record Official record
Conditions
Bipolar Disorder, Schizo Affective Disorder
Interventions
High-Definition Transcranial Electrical-Current Stimulation, High-Definition Transcranial Alternate-Current Stimulation, High-Definition Personalized Beta-Gamma Electrical Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 27, 2026, 5:09 AM EDT